This is the authors' abstract. We don't add key points for this paper.
While the abolition of REMS for clozapine expands access, the change could create confusion. Among the most relevant examples are mismatches between FDA recommendations for lifetime monitoring and the literature suggesting relaxation in monitoring after the period of highest neutropenia risk. The authors provide practical considerations for addressing this issue.
No takes yet. Share an insight, caveat, or question.
Meyer et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: